This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acorda Therapeutics Inc (ACOR)

NASDAQ: Health Care

Company Cash Flow
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Cash Flow From Operating Activities
Net Income (Loss) 11.06M 17.67M 16.44M 154.96M
Operating Gains/Losses 0.00 -147.00K -182.00K -701.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 744.00K -1.43M -4.46M -3.50M
(Increase) Decrease in Inventories -9.64M -665.00K -5.12M 7.43M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -825.00K 13.18M -5.79M 11.74M
(Decrease) Increase In Other Current Liabilities 0.00 108.00K 18.00K -725.00K
(Increase) Decrease In Other Working Capital -14.78M -11.29M -5.39M -12.28M
Other Non-Cash Items 21.99M 38.63M 25.05M 22.08M
Net Cash From Continuing Operations 38.48M 75.02M 39.28M 52.12M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 38.48M 75.02M 39.28M 52.12M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 356.50M 0.00 191.00M 264.75M
Purchases of Property, Plant & Equipment -7.07M -7.78M -7.16M -13.58M
Acquisitions 0.00 -476.15M -7.50M 0.00
Purchases of Short-Term Investments 0.00 0.00 -221.43M -322.45M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -85.24M -293.82M -45.09M -71.28M
Issuance of Debt 0.00 345.00M 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 18.10M 16.02M 12.79M 4.34M
Repayment of Long-Term Debt 0.00 0.00 -909.00K -1.25M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -307.00K -8.08M 91.00K 0.00
Net Cash From Financing Activities 17.79M 352.94M 11.97M 3.09M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -28.97M 134.13M 6.16M -16.08M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ACOR Acorda Therapeutics Inc

Chart of ACOR

Analysts Ratings for ACOR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

ACOR Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs